Entero Therapeutics, INC 8-K filings

Entero Therapeutics received a notice from Nasdaq for non-compliance with listing rules due to failing to hold an annual meeting within the required timeframe.

Entero Therapeutics subsidiary, ImmunogenX, received a notice of default on a $7.4 million loan, triggering immediate repayment and forcing the company to explore strategic alternatives.

Entero Therapeutics will merge with Journey Therapeutics, with Journey's shareholders acquiring 99% of Entero's equity, to form a combined entity focused on advancing novel cancer and gastrointestinal therapies.

Entero Therapeutics has received a notice from Nasdaq for failing to maintain a minimum share price of $1.00, placing it at risk of delisting.

Entero Therapeutics has entered a binding letter of intent to license clinical trial software from Data Vault Holdings, aiming to enhance its clinical trial processes and explore commercial opportunities.

Entero Therapeutics' subsidiary, ImmunogenX, has received a temporary suspension of a loan default notice from its lender, Mattress Liquidators, Inc.

Entero Therapeutics has appointed Machias Gini & O'Connell LLP as its new independent registered public accounting firm, effective August 27, 2024.

Entero Therapeutics received a notice from Nasdaq for failing to file its quarterly report on time, putting its listing status at risk.

Entero Therapeutics reports the resignation of a board member, appointment of a new audit committee member, and approval of post-employment medical insurance premiums for the CEO.

Entero Therapeutics' auditor, Forvis Mazars, resigned due to concerns about the company's ability to produce reliable financial information, leading to board and committee changes.

Entero Therapeutics, Inc. faces a severe financial crisis, defaulting on a nearly $7 million credit agreement, losing key board members, and undergoing a drastic restructuring to stay afloat.

Entero Therapeutics is focusing on advancing its lead product candidate, latiglutenase, into a pivotal Phase 3 trial in 2025 for the treatment of celiac disease.

Entero Therapeutics' Chief Scientific Officer, Dr. Jack Syage, has resigned from his role, effective immediately, as part of cost reduction measures, while remaining as President and a board member.

Entero Therapeutics raised approximately $1.9 million by inducing warrant holders to exercise existing warrants at a reduced price in exchange for new warrants.

Entero Therapeutics has transitioned Jack Syage from Chief Operating Officer to Chief Scientific Officer, effective immediately, while he remains President of the company.

Entero Therapeutics has appointed Forvis Mazars as its new independent auditor, effective June 1, 2024, following a merger involving its previous auditor, Mazars USA LLP.

Entero Therapeutics has filed an amendment to its 8-K report to include pro forma financial information following its merger with ImmunogenX.

First Wave BioPharma has changed its name to Entero Therapeutics, reflecting a strategic shift towards gastrointestinal therapies and a focus on advancing its lead asset, latiglutenase, for celiac disease.

First Wave BioPharma has entered into a securities purchase agreement to raise approximately $1.1 million through a registered direct offering and concurrent private placement.

First Wave BioPharma has filed an amendment to its original 8-K report to include the financial statements of ImmunogenX, following their recent merger.

First Wave BioPharma received a letter of reprimand from Nasdaq for failing to obtain shareholder approval before a significant share issuance, but the matter is now closed after the company took remedial action.

First Wave BioPharma will present two abstracts at the 2024 Digestive Disease Week Conference, highlighting new diagnostic methods and research in celiac disease.

First Wave BioPharma has acquired ImmunogenX in an all-stock transaction, adding latiglutenase, a Phase 3-ready celiac disease treatment, to its pipeline.

First Wave BioPharma has entered into a securities purchase agreement for a registered direct offering expected to generate approximately $4 million in gross proceeds.